Enabling Rapid High-Multiplex Immunoassay and Molecular Diagnostics at the Point of Need

Point-of-Care testing has been the Holy Grail of medical diagnostics for decades. Since the COVID-19 pandemic hit, the imperative need to develop novel capabilities that will allow for rapid, accessible, and precise immunoassay and molecular testing at any Point-of-Need, has become clear and undeniable.

Proactive Diagnostics' Q-SENS platform meets the essential criteria to fulfill this important goal:

​

• Central lab levels of sensitivity and specificity

• Results in 5-10 minutes

• Minimally invasive collection of miniature fluid samples (10 μl) that enables simple self-testing

• High multiplexing, allowing to probe for up to 32 biomarkers in a single run

• Low cost (100-200$ device and <1$ consumable per test)

• Quantitative detection, monitoring the kinetics rather than the end-point test result

Our platform technology enables the simultaneous detection of proteins, nucleic acids, and small molecules, unraveling a wide range of use-cases and possibilities. Using the Q-SENS, we aim to provide simple and accessible testing,  spanning multiple novel applications. 

The Q-SENS has shown exceptional performance on over 50 different assays, demonstrating its applicability toward a range of health conditions such as cardiovascular disease, infectious disease, oncology, chronic and acute inflammatory markers; and various tests in the veterinary, food safety, and dietary fields. 

We envision the Q-SENS becoming the platform of choice for Point-of-Need measuring of biomarkers wherever such capabilities have value.